Photoprotective Effects of a SPF50+ Sunscreen on Skin Genotoxicity Induced by Repeated Chronic Outdoor Sun Exposure

NCT ID: NCT05926791

Last Updated: 2023-07-03

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

23 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-06-28

Study Completion Date

2021-09-13

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Between 2 and 3 million non-melanoma skin cancers and 132,000 melanoma skin cancers occur globally each year. Sun protection continues to be a major public health issue and has always been a priority research area for Pierre Fabre laboratories. The involvement of ultraviolet radiation of the solar spectrum in skin carcinogenesis is well known, through its ability to damage the DNA of skin cells and the induction of oxidative processes.

The aim of this exploratory study is to perform the quantification of:

* DNA photoproducts excised from the genome by the biological repair systems in urine samples
* cellular DNA damage in the epidermis following chronic exposure to natural sunlight.

This study will allow us to better understand and quantify the benefit of sunscreens on photoinduced cellular damage and their elimination in urine.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This trial is a monocentric, exploratory, randomized, controlled, open-label, parallel-group study conducted in healthy adult subjects.

The target population consists of subjects who are accustomed to using few products or using low protection index during sun exposure.

The study area is the whole body for sun exposure. The target areas are the face and forearms for the samplings and measurements.

In this design, in order not to impose any strong constraint to the subjects in terms of sun exposure, the duration of the exposure period is left free and can vary between 5 and 21 days. Within this window, subjects can freely determine their sun exposure episodes (choice of time slot, number and duration). However, subjects have to expose themselves for at least 3 hours /day, for 5 days in the week prior to visit 2 (which will be scheduled no more than 3 days after their last sun exposure).

The study includes 3 visits:

* Visit 1: Inclusion (D1)
* Visit 2: Intermediate visit (D7 to D39)
* Visit 3: Wound healing evaluation and end of study (V2 + 15 days +/- 2 days)

The period of outdoor sun exposure varies between 5 and 21 days depending on the duration planned by the subjects themselves. This is also the duration of application of the investigational product for the subjects in group 1.

Visit 1 can be performed up to 15 days before the beginning of the sun exposure period and visit 2 up to 3 days after the last sun exposure.

The duration of participation for a subject varies between 20 and 56 days (from inclusion to the end of the study).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sun Damaged Skin

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Educated group with product

Subjects receiving the SPF50+ sunscreen product and a targeted educational action

* Route of administration: Topical
* Application duration: from 5 up to 21 days
* Application modalities: The investigational product will be applied during the outdoor sun exposure on all exposed parts of the body (face and body). The investigational product will be applied in sufficient amount to cover the exposed areas (2mg/cm2 recommended), 15 to 30 minutes before each sun exposure. The product should be reapplied as many times as required during sun exposure (systematic reapplication of the product after sweating and/or swimming and/or wiping).

Cosmetic product

Intervention Type OTHER

The educated group receives the cosmetic product SPF50+ according to the randomization list established at V1 and returns the products at V2

Control group

Subjects receiving neither product nor targeted education

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cosmetic product

The educated group receives the cosmetic product SPF50+ according to the randomization list established at V1 and returns the products at V2

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female adults aged between 18 and 55 years included
* Subject with a habit of using little or no sunscreen products with low protection index (SPF \< 25) during sun exposure.
* Subject's commitment to have a self-reported sun exposure of at least 3 hours per day for the 5 days of their last week of vacation
* Subjects agreeing not to expose themselves to UVs (natural or artificial) before the planned outdoor sun exposure period

Exclusion Criteria

1. \- Criteria related to the population:

* Smoker of more than 10 cigarettes per day containing nicotine, paper and/or electronic cigarette equivalent
* Subject having received on study areas artificial UV exposure or excessive, prolonged, and unprotected exposure to natural sunlight within the 4 weeks before the inclusion visit or planning one during the study
* Subject having performed excessive and prolonged physical activity (e.g. trail, long distance running, race…) within 7 days before the inclusion visit
2. \- Criteria related to the diseases / skin condition:

* Subject with a known history of photosensitivity (toxic, allergic)
* Subject with a known personal or family history of skin cancer
* Subject having hereditary or acquired disorders of hemostasis.
3. \- Criteria related to the treatments and/or products:

* Physical treatment (radiotherapy, phototherapy, chemical peeling, laser, ...) on the study area within 4 weeks before the inclusion visit or planned during the study.
* Systemic or topical treatment applied on the study area (e.g. anti-allergic, anti-inflammatory treatment) within two weeks before the inclusion visit, ongoing or planned during the study and likely to interfere with the study according to the investigator's assessment
* Use of anti-aging products (containing retinoids and / or α-hydroxy acids) on the target areas (face and/or forearms) in the 2 weeks before the inclusion visit.
* Systemic or topical treatment with photosensitizing or phototoxic potential (NSAIDs, antihistamines, psychotropic drugs, antidepressants, anti-migraine drugs, cyclines, quinolone, antibiotics, beta-blockers, etc.), taken or applied to the study area within the previous weeks, ongoing or planned during the study, and likely to interfere with the study according to the investigator's assessment
* Subject taking creatine dietary supplements and/or practicing prolonged fasting
Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Pierre Fabre Dermo Cosmetique

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Skin Research Center

Toulouse, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

DNAOUTDOOR

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

MoleGazer Development Feasibility Study
NCT05015816 ACTIVE_NOT_RECRUITING NA